Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult Drug Administration Schedule Comparative Study 80 and over Clinical Trial Randomized Controlled Trial Multicenter Study drug therapy combination viral load ribavirin / administration & dosage* viral / blood* phase ii chronic / complications chronic / drug therapy* antiviral agents / administration & dosage* treatment failure polyethylene glycols / therapeutic use hepacivirus / genetics interferons / therapeutic use sulfonamides quinoxalines / administration & dosage* eric lawitz liver cirrhosis / etiology* pmid:25467591 doi:10.1016/s0140-6736(14)61795-5 edward gane barbara haber amides benzofurans / administration & dosage* carbamates cyclopropanes imidazoles / administration & dosage*